Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +0.79% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $20.87 today, the market must believe free cash flow compounds 12.5%/yr for a decade (off $19M normalized FCF).
The market's 12.5% is more optimistic than its 9-yr track record.
2-stage DCF · 0.02B shares · net debt $71M
mean -1.8% · volatility σ 23% · implied rate exceeded in 1/9 yrs
Central path = implied 12.5%/yr growth; shaded band = ±1σ (23%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| NRC | $472M | 0.4× | — | 3.4× | -4.0% | — | 8.4% | 82.9% | 13.0% | — | 117 |
Peers = companies sharing NRC's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $137.4M 100.0% | $143.1M 100.0% | $148.6M 100.0% | $151.6M 100.0% | $148.0M 100.0% | $133.3M 100.0% | $128.0M 100.0% | $119.7M 100.0% | $117.6M 100.0% | $109.4M 100.0% |
| Selling, General & Admin | $54.8M 39.9% | $44.9M 31.4% | $46.6M 31.4% | $42.7M 28.2% | $39.0M 26.3% | $34.4M 25.8% | $33.0M 25.8% | $31.4M 26.2% | $29.7M 25.3% | $28.4M 25.9% |
| Total Operating Expenses | $114.8M 83.6% | $107.9M 75.4% | $108.5M 73.0% | $105.0M 69.3% | $97.7M 66.0% | $91.1M 68.4% | $84.9M 66.4% | $84.4M 70.5% | $83.3M 70.9% | $78.2M 71.5% |
| Operating Income | $22.6M 16.4% | $35.2M 24.6% | $40.0M 27.0% | $46.5M 30.7% | $50.3M 34.0% | $42.7M 32.0% | $43.0M 33.6% | $35.3M 29.5% | $34.2M 29.1% | $31.2M 28.5% |
| Interest Expense | $4.8M 3.5% | $2.6M 1.8% | $862K 0.6% | $1.2M 0.8% | $1.7M 1.1% | $1.8M 1.4% | $2.1M 1.6% | $1.5M 1.3% | $82K 0.1% | $190K 0.2% |
| Interest & Investment Income | $111K 0.1% | $125K 0.1% | $820K 0.6% | $168K 0.1% | $14K 0.0% | $18K 0.0% | $37K 0.0% | $62K 0.1% | $96K 0.1% | $47K 0.0% |
| Other Income (Expense), net | -$4.7M -3.5% | -$2.5M -1.8% | -$83K -0.1% | -$3.7M -2.5% | -$1.6M -1.1% | -$1.2M -0.9% | -$2.5M -2.0% | -$566K -0.5% | $64K 0.1% | $159K 0.1% |
| Pretax Income | $17.8M 13.0% | $32.7M 22.9% | $40.0M 26.9% | $42.8M 28.2% | $48.6M 32.9% | $41.5M 31.1% | $40.5M 31.7% | $34.7M 29.0% | $34.3M 29.2% | $31.4M 28.7% |
| Income Tax Expense | $6.2M 4.5% | $7.9M 5.5% | $9.0M 6.1% | $11.0M 7.3% | $11.2M 7.5% | $4.2M 3.2% | $8.1M 6.3% | $4.7M 3.9% | $11.3M 9.6% | $10.8M 9.9% |
| Net Income | $11.6M 8.4% | $24.8M 17.3% | $31.0M 20.8% | $31.8M 21.0% | $37.5M 25.3% | $37.3M 28.0% | $32.4M 25.3% | $30.0M 25.1% | $22.9M 19.5% | $20.5M 18.8% |
| Per Share | ||||||||||
| EPS (Basic) | $50.00 | $1.05 | $1.26 | $1.28 | $1.47 | $1.48 | $1.30 | — | — | — |
| EPS (Diluted) | $50.00 | $1.04 | $1.25 | $1.27 | $1.46 | $1.45 | $1.26 | — | — | — |
| Weighted Avg Shares (Basic) | 22.4M | 23.7M | 24.5M | 24.9M | 25.4M | 25.2M | 24.8M | — | — | — |
| Weighted Avg Shares (Diluted) | 22.4M | 23.7M | 24.7M | 25.1M | 25.6M | 25.7M | 25.7M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 70% of free cash flow, leaving room to grow it and fund buybacks. Last year: $11M dividends + $20M buybacks = $31M returned on $16M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 13%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $4M covers the $0 due within a year 4139000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2018-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~6.3% on $75M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 13-yr range · 38th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 9.0× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| SG&A | 26.2 | 25.8 | 25.8 | 26.3 | 28.2 | 31.4 | 31.4 | 39.9 |
| Operating Income | 29.5 | 33.6 | 32.0 | 34.0 | 30.7 | 27.0 | 24.6 | 16.4 |
| Income Tax | 3.9 | 6.3 | 3.2 | 7.5 | 7.3 | 6.1 | 5.5 | 4.5 |
| Net Income | 25.1 | 25.3 | 28.0 | 25.3 | 21.0 | 20.8 | 17.3 | 8.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on NRC: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position